ARTV Artiva Biotherapeutics Inc

$ARTV = today's biotech gut punch Halting development of AlloNK in RA after two patient deaths (not good considering NK cell approach was thought to be safer)

$ARTV wow what a gut punch to the investors Looks like some red flags for a while though with all the insider selling, etc

$ARTV is it smart to buy right now?? And are these stock price predictions gonna happen in the next year...i was up to 50k now im down to 25k im still up but i just dont get ehy its dropping since it has high prediction can someone who knows lots about this let me know what they think

$ARTV SEC 8-K filed 10/27: On 10/22, the board approved the full termination of its lead pipeline AlloNK. Reasons: long-term follow-up failed to confirm durable efficacy, plus a recent Grade 5 fatal adverse event. Roughly 94% of staff to be laid off, and the company is exploring strategic alternatives including sale or liquidation. It raised ~$300M back in May and was still advancing the RA Phase 3 program plus RMAT designation in August. Just ten weeks from a “transformative quarter” to liquidation. Both Needham and Wedbush cut their ratings to Hold on the day. Contrarian-bullish on the stub!!!

$ARTV Anyone else notice those 2000 $5 18DEC26c sold for $0.3 at the open yesterday, because I did. It's trading way below market cap/cash on hand. They'll most likely do a reverse merger with GC to recoup the losses. Leerink Partners is going to find them a nice suitor, if it isn't going to be GC, but I don't think GC wants to let all of that IP and money get away. The stock is going to bounce back up above $5.

$ARTV Terrible news for the patients, and their families. Hopefully it’s something that can be sorted out and not a read block for the technology/approach.

Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months $ARTV $XBI https://stocktwits.com/news/equity/markets/artiva-scraps-development-of-lead-drug-candidate-after-patient-deaths/cZUe90FRBCW

$ARTV 🏥 Artiva Biotherapeutics, Inc. is discontinuing development of AlloNK (AB-101), including a planned phase 3 pivotal trial, after updated longer-term data did not meet its durability threshold, and will reduce its workforce by approximately 94% while evaluating strategic alternatives. Prioritized by relevance